Mario Rovirosa – CEO, Ferrer
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Founded in 1959, Ferrer is a Spanish multinational privately-held pharmaceutical company headquartered in Barcelona with a presence in over 90 countries. They operate in the pharmaceutical, health, fine chemicals (API), and food sectors. The company has expertise in the fields of cardiology, central nervous system, dermatology, gastroenterology, metabolism, oncology, musculoskeletal system, paediatrics, pain management, and respiratory.
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Alejandro Mora, Ferrer’s country manager for Central America & Caribbean, discusses the complexity of the region’s healthcare systems, the company’s strategy to compete against local players, and the importance for…
Xavier Rams, General Director at Ferrer Mexico, explains the importance of aligning corporate strategy to public healthcare goals in order to succeed in the dynamic Mexican environment and showcases the…
CPH Pharma was the oldest running pharmaceutical company in Portugal until its acquisition by Grupo Ferrer in 2008. Since then, the company has continued to thrive in the marketplace despite…
Our business model is new in the Chilean market and enables us with great flexibility and allows us to focus on demand generation. For Ferrer this is a great window…
In the second part of a two-part interview, Generika Philippines co-founders, Teodoro Ferrer and Julien Bello, go on to discuss the future of generic medicines in the Philippines, the compnay’s…
In part one of a two-part interview, Generika Philippines co-founders Teodoro Ferrer and Julien Bello discuss what led them to start the company, the changing mentality among the Filipino population…
A roundup of the biggest pharma news from Spain, including Grifols’ comeback after a turbulent 2024 when the company lost 30 percent of its market value; Almirall’s revenue and value…
While Europe has lost some of its global share of clinical trials to China and the US, it remains a clinical research stronghold. Three years into the Accelerating Clinical Trials…
A roundup of some of the top stories coming out of Spain’s life sciences sector, including Brookfield’s ongoing interest in Grifols; Rovi’s change of heart about selling its CDMO business;…
Almost 2,500 attendees flocked to Madrid last week for the 2024 edition of Clinical Trials on Alzheimer’s Disease (CTAD). The first European edition of the conference since 2018 was punctuated…
This year’s European Society of Medical Oncology (ESMO) was the largest ever. Over 33,000 people attended ESMO Congress 2024 at Barcelona’s cavernous Fira Gran Via conference centre, where 5,000 abstracts…
Some of the biggest stories coming out of Spain’s pharma industry, including Brookfield’s bid for a troubled Grifols; Esteve’s Spanish plant expansion; Rovi’s offers for a potential buyout of its…
A roundup of the biggest stories emerging from Spain’s pharma industry: Grifols pushes to improve governance after accusations of overstated earnings; Rovi and Insud join forces to create Spain’s first…
Brazilian national Maria Fernanda Prado, who began her career in pharma more than 20 years ago, has been at Janssen/Johnson & Johnson for more than half of that time. She…
Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is…
Having forged a solid position in clinical research in 2020 and 2021 when it became the fourth nation in the world and the first in Europe for studies conducted around…
The European Union’s just-released and first essential medicines list is the latest in a series of measures designed to limit the bloc’s reliance on countries outside its borders and avoid…
The COVID-19 pandemic and subsequent shortages of essential medicines and APIs laid bare Europe’s reliance on suppliers outside its borders. To combat this issue and ensure that Europe is better…
See our Cookie Privacy Policy Here
